Company Name: |
TargetMol Chemicals Inc.
|
Tel: |
4008200310 |
Email: |
marketing@tsbiochem.com |
Products Intro: |
Product Name:SM1-71;SM1 71,SM171,SM-1-71 CAS:2088179-99-9 Purity:98% Package:200 mg
|
Company Name: |
Suzhou Zhixin Biotechnology Co., Ltd.
|
Tel: |
0512-65118909 15162312715 |
Email: |
sales@szzxbio.com |
Products Intro: |
Product Name:SM1-71 CAS:2088179-99-9 Purity:98%+ Package:1g;10g;100g
|
Company Name: |
Suzhou Haiben Pharmaceutical Co., Ltd
|
Tel: |
14760821013 14760821013 |
Email: |
1816280386@qq.com |
Products Intro: |
Product Name:SM1-71 CAS:2088179-99-9 Purity:98.5% HPLC Package:10g;100g;1kg;10kg
|
|
Product Name: | SM1-71 | Synonyms: | SM1-71;SM1 71,SM171,SM-1-71;2-Propenamide, N-[2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- | CAS: | 2088179-99-9 | MF: | C24H26ClN7O | MW: | 463.96 | EINECS: | | Product Categories: | | Mol File: | 2088179-99-9.mol | ![SM1-71 Structure](CAS/20210305/GIF/2088179-99-9.gif) |
| SM1-71 Chemical Properties |
density | 1.333±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | form | Solid | pka | 13.07±0.70(Predicted) | color | White to off-white |
| SM1-71 Usage And Synthesis |
Biological Activity | SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines[1][2][3].
SM1-71 (0.001-100 μM; 72 h) potently inhibits the proliferation of H23 and Calu-6 non-small cell lung cancer cell lines with a concentration-dependent manner[1].SM1-71 (72 h) induces potent cytotoxicity with nanomolar values for GR50 and negative GRmax values in eight of 11 cancer cell lines[2]. | References | [1]. Rao S, et, al. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chem Biol. 2019 Jun 20; 26(6): 818-829.e9. [2]. Rao S, et, al. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. J Biol Chem. 2019 May 24;294(21):8664-8673. [3]. Tan L, et, al. Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017 Feb 1; 25(3): 838-846. |
| SM1-71 Preparation Products And Raw materials |
|